Hongwei Zhao, Yubao Zhang, Jianmin Sun, Chao Zhan, Liang Zhao
Oncology Research, Vol.23, No.5, pp. 237-248, 2015, DOI:10.3727/096504016X14562725373671
Abstract Raltitrexed (RTX) is an antimetabolite drug used as a chemotherapeutic agent for treating colorectal cancer,
malignant mesothelioma, and gastric cancer. The antitumor capacity of RTX is attributed to its inhibitory
activity on thymidylate synthase (TS), a key enzyme in the synthesis of DNA precursors. The current study is
aimed at investigating the potential antitumor effects of RTX in liver cancer. Using the HepG2 cell line as an
in vitro model of liver cancer, we evaluated the effects of RTX on cell proliferation employing both a WST-8
assay and a clone formation efficiency assay. In addition,… More >
Login
Register
